Unexpected findings show that the body’s own immune system destroys retinal cells.
Glaucoma, a disease that afflicts nearly 70 million people worldwide, is something of a mystery despite its prevalence. Little is known about the origins of the disease, which damages the retina and optic nerve and can lead to blindness.
A new study from MIT and Massachusetts Eye and Ear has found that glaucoma may in fact be an autoimmune disorder. In a study of mice, the researchers showed that the body’s own T cells are responsible for the progressive retinal degeneration seen in glaucoma. Furthermore, these T cells appear to be primed to attack retinal neurons as the result of previous interactions with bacteria that normally live in our body.
The discovery suggests that it could be possible to develop new treatments for glaucoma by blocking this autoimmune activity, the researchers say.
“This opens a new approach to prevent and treat glaucoma,” says Jianzhu Chen, an MIT professor of biology, a member of MIT’s Koch Institute for Integrative Cancer Research, and one of the senior authors of the study, which appears in Nature Communications on Aug. 10.
Dong Feng Chen, an associate professor of ophthalmology at Harvard Medical School and the Schepens Eye Research Institute of Massachusetts Eye and Ear, is also a senior author of the study. The paper’s lead authors are Massachusetts Eye and Ear researchers Huihui Chen, Kin-Sang Cho, and T.H. Khanh Vu.
Genesis of glaucoma
One of the biggest risk factors for glaucoma is elevated pressure in the eye, which often occurs as people age and the ducts that allow fluid to drain from the eye become blocked. The disease often goes undetected at first; patients may not realize they have the disease until half of their retinal ganglion cells have been lost.
Most treatments focus on lowering pressure in the eye (also known as intraocular pressure). However, in many patients, the disease worsens even after intraocular pressure returns to normal. In studies in mice, Dong Feng Chen found the same effect.
“That led us to the thought that this pressure change must be triggering something progressive, and the first thing that came to mind is that it has to be an immune response,” she says.
To test that hypothesis, the researchers looked for immune cells in the retinas of these mice and found that indeed, T cells were there. This is unusual because T cells are normally blocked from entering the retina, by a tight layer of cells called the blood-retina barrier, to suppress inflammation of the eye. The researchers found that when intraocular pressure goes up, T cells are somehow able to get through this barrier and into the retina.
The Mass Eye and Ear team then enlisted Jianzhu Chen, an immunologist, to further investigate what role these T cells might be playing in glaucoma. The researchers generated high intraocular pressure in mice that lack T cells and found that while this pressure induced only a small amount of damage to the retina, the disease did not progress any further after eye pressure returned to normal.
Further studies revealed that the glaucoma-linked T cells target proteins called heat shock proteins, which help cells respond to stress or injury. Normally, T cells should not target proteins produced by the host, but the researchers suspected that these T cells had been previously exposed to bacterial heat shock proteins. Because heat shock proteins from different species are very similar, the resulting T cells can cross-react with mouse and human heat shock proteins.
To test this hypothesis, the team brought in James Fox, a professor in MIT’s Department of Biological Engineering and Division of Comparative Medicine, whose team maintains mice with no bacteria. The researchers found that when they tried to induce glaucoma in these germ-free mice, the mice did not develop the disease.
The researchers then turned to human patients with glaucoma and found that these patients had five times the normal level of T cells specific to heat shock proteins, suggesting that the same phenomenon may also contribute to the disease in humans. The researchers’ studies thus far suggest that the effect is not specific to a particular strain of bacteria; rather, exposure to a combination of bacteria can generate T cells that target heat shock proteins.
One question the researchers plan to study further is whether other components of the immune system may be involved in the autoimmune process that gives rise to glaucoma. They are also investigating the possibility that this phenomenon may underlie other neurodegenerative disorders, and looking for ways to treat such disorders by blocking the autoimmune response.
“What we learn from the eye can be applied to the brain diseases, and may eventually help develop new methods of treatment and diagnosis,” Dong Feng Chen says.
The Latest on: Glaucoma
via Google News
The Latest on: Glaucoma
- Ocular Therapeutix™ Presents Interim Topline Data from the Phase 1 Clinical Trial of OTX-TIC in Patients with Primary Open Angle Glaucoma or Ocular Hypertension at the 10 th ...on January 20, 2021 at 10:00 am
Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative the ...
- Skye Bioscience Is Utilizing A Novel THC-Derivative To Treat Glaucomaon January 20, 2021 at 5:20 am
Skye Bioscience, formally Emerald Bioscience, was one of the sponsors for the Benzinga Global Small Cap Conference that took place on December 8-9, 2020. The information contained in this article in ...
- Glaucoma Therapeutics Market | 2021 Healthcare Industry Analysis By COVID-19 Impact With Global Forecast To 2026on January 19, 2021 at 10:52 am
Healthcare Industry Analysis By COVID-19 Impact With Global Forecast To 2026 "Glaucoma Therapeutics Market | 2021 Healthcare Industry Analysis By COVID-19 Impact With Global Forecast To 2026." ...
- Study Finds Potential Biomarkers for Distinguishing Glaucoma Subtypeson January 19, 2021 at 9:38 am
Results from a prospective observational study showed aqueous transforming growth factor beta and autotaxin exhibited high diagnostic performance in detecting glaucoma subtypes and could serve as ...
- Global Micro Invasive Glaucoma Surgery (MIGS) Devices Market 2020 Growth Opportunities, Market Shares, Future Estimations and Key Countries by 2025on January 18, 2021 at 7:37 pm
MarketsandResearch.biz has published the latest and most trending report entitled Global Micro Invasive Glaucoma Surgery (MIGS) Devices Market 2020 by Manufacturers, Type and Application, Forecast to ...
- Eye membrane removal may help transplanted cells reverse glaucoma damageon January 16, 2021 at 2:56 pm
Glaucoma is a serious eye disease that can gradually cause vision loss, which is currently irreversible. But in a new cell culture study scientists found that removing a membrane at the back of the ...
- Glaucoma awareness is importanton January 14, 2021 at 9:21 am
January is National Glaucoma Awareness Month. Glaucoma is one of the leading causes of blindness in the United States and is estimated to affect 3 ...
- Glaucoma awareness: A secret sight-stealing diseaseon January 12, 2021 at 4:00 pm
More than 3 million people in the United States are currently diagnosed with glaucoma. The National Eye Institute anticipates ...
- Focus on Eyes: Don’t let glaucoma steal your sighton January 12, 2021 at 4:06 am
Many people have glaucoma and don’t know it because the visual loss is gradual and mostly painless. Glaucoma is an eye disease that involves damage to the optic nerve, which connects the eye to brain.
via Bing News